Cumberland Pharmaceuticals (CPIX) Stock Price, News & Analysis

Company Overview

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Key Stats

• Today's Range: $5.31 to $6.05
• 50-Day Range: $2.12 to $6.19
• 52-Week Range: $1.04 to $7.19
• Volume: 168,177 shs
• Average Volume: 2.80 million shs
• Market Capitalization: $74.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Cumberland Pharmaceuticals Stock Analysis - MarketRank™

Cumberland Pharmaceuticals scored higher than 23% of companies evaluated by MarketBeat, and ranked 855th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Cumberland Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cumberland Pharmaceuticals is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cumberland Pharmaceuticals is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cumberland Pharmaceuticals has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.44% of the float of Cumberland Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Cumberland Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cumberland Pharmaceuticals has recently decreased by 56.34%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cumberland Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Cumberland Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.44% of the float of Cumberland Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Cumberland Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cumberland Pharmaceuticals has recently decreased by 56.34%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.38

News Sentiment

Cumberland Pharmaceuticals has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cumberland Pharmaceuticals this week, compared to 16 articles on an average week.

Search Interest

15 people have searched for CPIX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

3 people have added Cumberland Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cumberland Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

43.30% of the stock of Cumberland Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.51% of the stock of Cumberland Pharmaceuticals is held by institutions.

CPIX Stock Analysis - Frequently Asked Questions

How have CPIX shares performed this year?

Cumberland Pharmaceuticals' stock was trading at $2.37 at the start of the year. Since then, CPIX stock has increased by 124.1% and is now trading at $5.31.
View the best growth stocks for 2025 here.

How were Cumberland Pharmaceuticals' earnings last quarter?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released its earnings results on Thursday, November, 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. The specialty pharmaceutical company earned $9.09 million during the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative trailing twelve-month return on equity of 9.50%.

Who are Cumberland Pharmaceuticals' major shareholders?

Top institutional shareholders of Cumberland Pharmaceuticals include Renaissance Technologies LLC (3.61%), Dimensional Fund Advisors LP (1.94%), Bridgeway Capital Management LLC (1.31%) and Two Sigma Investments LP (0.27%). Insiders that own company stock include Kenneth Krogulski, James Jones and Caroline Young.
View institutional ownership trends.

How do I buy shares of Cumberland Pharmaceuticals?

Shares of CPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cumberland Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cumberland Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Exxon Mobil (XOM), Netflix (NFLX) and Intel (INTC).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CPIX
• CUSIP: 23077010
• CIK: 1087294
• Web: www.cumberlandpharma.com
• Phone: (615) 255-0068
• Fax: 615-255-0094
• Employees: 80
• Year Founded: 1999

Profitability

• EPS (Most Recent Fiscal Year): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,280,000.00
• Net Margins: -29.54%
• Pretax Margin: -29.32%
• Return on Equity: -9.50%
• Return on Assets: -3.19%

Debt

• Debt-to-Equity Ratio: 0.41
• Current Ratio: 1.13
• Quick Ratio: 0.99

Sales & Book Value

• Annual Sales: $39.55 million
• Price / Sales: 1.89
• Cash Flow: $0.59 per share
• Price / Cash Flow: 8.95
• Book Value: $1.96 per share
• Price / Book: 2.71

Miscellaneous

• Outstanding Shares: 14,040,000
• Free Float: 7,962,000
• Market Cap: $74.55 million
• Optionable: Optionable
• Beta: 0.12